Navigation Links
EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
Date:3/21/2013

rate purposes."

Dr. Ren continued, "In terms of our outlook for 2013, we remain focused on building a leading oncology enterprise that integrates US and China strategies and resources for cost effective drug development. We intend to achieve the following objectives:

  • Continue the development of ENMD-2076, including initiating global clinical trials with sites in China under our U.S. FDA IND, and in parallel, pursuing local development in China under SFDA;
  • Pursue an additional clinical-stage drug candidate to add to our pipeline;
  • Further develop our regulatory and clinical capability in China.
  • With the foundation established through our achievements in 2012 and our recent financing, we believe that we are well positioned to accomplish these objectives and look forward to continued progress in 2013." 

    About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed, Inc. recently announced the initiation of a Phase 2 study of ENMD-2076 in triple-negative breast cancer and the initiation of a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

    About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor wit
    '/>"/>

    SOURCE EntreMed, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. EntreMed Reports First Quarter 2012 Financial Results
    2. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
    3. EntreMed Reports Second Quarter 2012 Financial Results
    4. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
    5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
    6. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
    7. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
    8. EntreMed To Raise $10.7 Million In Registered Direct Offering
    9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    10. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    11. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/24/2014)... , Nov. 24, 2014 Juno ... Breakthrough Therapy Designation to the company,s JCAR015 chimeric ... the treatment of relapsed or refractory B-cell acute ... partner, Memorial Sloan Kettering Cancer Center, where Phase ... "The FDA,s action is important news for ...
    (Date:11/24/2014)... 24, 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced today that Sergio Traversa , ... LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, ... the Luxe Sunset Bel Air Hotel, which is located ... California . The presentation is scheduled ...
    (Date:11/24/2014)... -- GlySens Incorporated announced today that it has been awarded ... Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), ... The grant is intended to support human clinical evaluation ... glucose monitoring system.  Final preparations for launch of the ... before the end of 2014. "We are ...
    Breaking Medicine Technology:Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
    ... Oct. 15 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Annual NewsMakers in the Biotech Industry Conference on Friday, ... a.m. Eastern Time.  The session may be accessed through ... Investor Relations page.  An archived version of the presentation ...
    ... CINCINNATI, Oct. 15  "This is a significant decision in ... advocates and the entire pharmaceutical industry," commented Benjamin H. ... an en banc hearing was not necessary and that ... plaintiff,s claim that the diet drug Redux (commonly known ...
    Cached Medicine Technology:
    (Date:11/26/2014)... For those with a New Year’s resolution to ... classes at the University of Colorado Anschutz Health and ... for. The 45- 60 minute classes have just started and ... fitness club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, ... aimed at fast results , By focusing on low ...
    (Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. Hill, ... from The American Association of Nurse Practitioners ... nurse practitioners. The Distinguished Preceptorship Award recognizes the ... significant contribution toward increasing the awareness and acceptance ... (AANP) is the largest full-service national professional membership ...
    (Date:11/26/2014)... (HealthDay News) -- Vultures have developed highly specialized ways ... eating dead animals, researchers report. The new research ... faces and in the guts of 50 turkey vultures ... the faces of the vultures had more than 500 ... guts, the study found. The findings suggest that ...
    (Date:11/26/2014)... to peanut protein in household dust may increase the ... condition eczema, a new study reveals. About 2 ... allergic to peanuts. And severe eczema in infants has ... researchers noted. The new study included 359 infants ... the amount of peanut protein the children were exposed ...
    (Date:11/26/2014)... 25, 2014 (HealthDay News) -- Parents need to take ... concussions, an expert warns. Parents must make sure ... standard, Dr. David Dodick, chair of the American Migraine ... Clinic College of Medicine in Scottsdale, Ariz. in an ... release. Any coach involved with teens sports needs ...
    Breaking Medicine News(10 mins):Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
    ... flow may be better conditioned to survive a full-blown ... University of Cincinnati (UC). , In a five-year ... when the heart experiences short periods of stress, either ... activates a protective molecular pathwayknown as JAK-STATthat protects the ...
    ... WuXi PharmaTech (NYSE:,WX), China,s premier provider of pharmaceutical R&D ... temporarily assume the role of,the Chairman of the Audit ... of the Audit Committee was previously held by Mr. ... his vacation., Mr. Cuong Viet Do has served ...
    ... drank more heavily than male peers, field study finds ... on-the-scene study of college drinking behavior shows that parties ... while themed parties encourage college women to drink more ... of college drinking have relied largely on individual behavior ...
    ... - President of cbm, Prof. Allen Foster,announces that cbm ... persons,with disability, not just persons with visual loss., ... Christoffel Blinden,Mission, and Christian Blind Mission, has worked to ... for persons,with visual loss., "The organization has decided ...
    ... 4 Health Secretary Dr.,Calvin B. Johnson today invited ... exhibit at the Farm Show for free health,screenings, fun ... Body Shop is a fun place for kids and ... running in peak condition," Dr. Johnson said.,"Everyone should stop ...
    ... International,Associates, Inc, administrator for the HealthShares(TM) Indexes, a ... Funds, today,announced that effective at the opening of ... ARQL ) will replace Coley Pharmaceutical, Inc.,(Nasdaq: ... Index. Coley,Pharmaceutical is being acquired by Pfizer, Inc. ...
    Cached Medicine News:Health News:Mini 'stress tests' could help condition heart to survive major attack 2Health News:WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee 2Health News:College Drinking Games Lead to Higher Blood Alcohol Levels 2Health News:cbm Expanding its Mandate 2Health News:QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index 2
    The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
    An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
    Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
    All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
    Medicine Products: